Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725032 | 1.00 | ESR1 (0.76) | ESR1KCNH2 | |
| SCHEMBL17839580 | 1.00 | ESR1 (0.76) | ESR1KCNH2 | |
| SCHEMBL29358188 | 0.92 | ESR1 (0.75) | ESR1 | |
| SCHEMBL20528169 | 0.92 | ESR1 (0.75) | ESR1 | |
| SCHEMBL23280600 | 0.92 | ESR1 (0.75) | ESR1 | |
| SCHEMBL30124032 | 0.92 | ESR1 (0.70) | ESR1KCNH2 | |
| SCHEMBL17839808 | 0.92 | ESR1 (0.70) | ESR1KCNH2 | |
| SCHEMBL17839229 | 0.92 | ESR1 (0.79) | ESR1KCNH2 | |
| SCHEMBL25002290 | 0.92 | ESR1 (0.79) | ESR1KCNH2 | |
| SCHEMBL30123864 | 0.92 | ESR1 (0.79) | ESR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760623-B1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-18 | — | — | EP | claimed |
| US-20250114338-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-113490850-B | Diagnostic and therapeutic methods for treating breast cancer | 基因泰克公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | ESR2, GPER1, ESR1 | ESR1 3/4885KCNH2 4144/4885 |
| US-20250114338-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ESR1 3/4885KCNH2 4144/4885 |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ESR1 3/4885KCNH2 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.